Patents by Inventor Tomohiro Emura

Tomohiro Emura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of administrating an anticancer drug containing ?, ?, ?-trifluorothymidine and thymidine phosphorylase inhibitor
    Patent number: 7799783
    Abstract: The present invention relates to a method for treating a cancer comprising orally administering a composition containing ?,?,?-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 20 to 80 mg/m2/day in terms of FTD in 2 to 4 divided portions per to patients in need of the treatment.
    Type: Grant
    Filed: January 26, 2005
    Date of Patent: September 21, 2010
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Tomohiro Emura, Akira Mita
  • Method of administrating an anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
    Publication number: 20060167031
    Abstract: The present invention relates to a method for treating a cancer comprising orally administering a composition containing ?,?,?-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 20 to 80 mg/m2/day in terms of FTD in 2 to 4 divided portions per to patients in need of the treatment.
    Type: Application
    Filed: January 26, 2005
    Publication date: July 27, 2006
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Tomohiro Emura, Akira Mita
  • Uracil derivatives and antitumor effect potentiator and antitumor agent containing the same
    Patent number: 6294535
    Abstract: The invention relates to novel uracil derivatives having excellent inhibiting effects on human derived thymidine phosphorylates and anti-tumor activity. The pharmaceutical compositions, anti-tumor potentiators and antitumor agents containing such novel compounds, and a process for their preparation and use are described.
    Type: Grant
    Filed: December 9, 1999
    Date of Patent: September 25, 2001
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Shingo Yano, Yukio Tada, Hideki Kazuno, Tsutomu Sato, Junichi Yamashita, Norihiko Suzuki, Tomohiro Emura, Masakazu Fukushima, Tetsuji Asao
  • Cancerous metastasis inhibitors containing uracil derivatives
    Patent number: 6255314
    Abstract: This invention provides a drug which has inhibitory activities against thymidine phosphorylase and inhibits metastasis of a cancer. Specifically, this invention relates to a cancerous metastasis inhibitor comprising, as an active ingredient, a uracil derivative represented by the following formula (1): wherein R1 represents a chlorine, bromine or iodine atom or a cyano or lower alkyl group and R2 represents a substituted or unsubstituted 4-8 membered hetero-cyclic group having nitrogen atoms or a substituted or unsubstituted amidinothio, guanidino, (lower alkyl)amidino, amino or like group, or a salt thereof.
    Type: Grant
    Filed: May 26, 1998
    Date of Patent: July 3, 2001
    Assignee: Taiho Charmaceutical Co., Ltd.
    Inventors: Kazutaka Miyadera, Tomohiro Emura, Konstanty Wierzba, Yuji Yamada
  • Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
    Patent number: 6159969
    Abstract: The invention relates to novel uracil derivatives having excellent inhibiting effects of human derived thymidine phosphorylase and anti-tumor activity. The pharmaceutical compositions, anti-tumor potentiators, antitumor agents containing such novel compounds, and a process for their preparation and use is described.
    Type: Grant
    Filed: January 12, 1998
    Date of Patent: December 12, 2000
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Shingo Yano, Yukio Tada, Hideki Kazuno, Tsutomu Sato, Junichi Yamashita, Norihiko Suzuki, Tomohiro Emura, Masakazu Fukushima, Tetsuji Asao
  • Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
    Patent number: 5744475
    Abstract: The invention relates to novel uracil derivatives having excellent inhibiting effects of human derived thymidine phosphorylase and anti-tumor activity. The pharmaceutical compositions, anti-tumor potentiators, antitumor agents containing such novel compounds, and a process for their preparation and use is described.
    Type: Grant
    Filed: November 21, 1996
    Date of Patent: April 28, 1998
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Shingo Yano, Yukio Tada, Hideki Kazuno, Tsutomu Sato, Junichi Yamashita, Norihiko Suzuki, Tomohiro Emura, Masakazu Fukushima, Tetsuji Asao
  • Method of administrating an anticancer drug containing ?, ?, ?-trifluorothymidine and thymidine phosphorylase inhibitor
    Patent number: RE46284
    Abstract: The present invention relates to a method for treating a cancer comprising orally administering a composition containing ?,?,?-trifluorothymidine (FTD) and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride in a molar ratio of 1:0.5 at a dose of 20 to 80 mg/m2/day in terms of FTD in 2 to 4 divided portions per to patients in need of the treatment.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: January 24, 2017
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Tomohiro Emura, Akira Mita